β‐Sitosterol Ameliorates Ulcerative Colitis Through Modulation of the AMPK/MLCK Anti‐Inflammatory Pathway
Journal of Biochemical and Molecular Toxicology · 2025-06 · 39 (6)
DOI: 10.1002/jbt.70287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, online erschienen am 22.05.2025. Verfasst von Yuansen Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, China. Hauptthemen laut MEDLINE: Sitosterols, Colitis, Ulcerative, AMP-Activated Protein Kinases, Anti-Inflammatory Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: This study was supported by the Science and Technology Program of Wenzhou (Y2023393)..
Abstract (Originalsprache)
Ulcerative colitis (UC), a common inflammatory bowel disease, has become increasingly prevalent worldwide, posing significant health challenges. This study explored the anti‐inflammatory effects of β‐sitosterol on UC and its underlying molecular mechanisms. Using a dextran sulfate sodium (DSS)‐induced colitis model in male C57BL/6 mice, the therapeutic potential of β‐sitosterol at low (2 mg/kg) and high (6 mg/kg) doses was compared with sulfasalazine (300 mg/kg) as a positive control. Disease progression was assessed through Disease Activity Index (DAI) scores, histological analysis, and inflammatory marker expression. β‐sitosterol significantly ameliorated colonic inflammation, demonstrated by lower DAI scores, improved histological architecture, and reduced levels of inflammatory mediators, including NO, MPO, IL‐6, and iNOS, while upregulating the anti‐inflammatory cytokine IL‐10. Mechanistically, β‐sitosterol promoted AMP‐activated protein kinase (AMPK) expression and suppressed myosin light chain kinase (MLCK) expression. These findings were validated in vitro using LPS‐stimulated Caco‐2 cells, where β‐sitosterol decreased inflammatory marker levels and modulated AMPK/MLCK signaling. Notably, the use of Compound C, an AMPK inhibitor, reversed these effects by suppressing AMPK activity and restoring MLCK expression, confirming that the anti‐inflammatory actions of β‐sitosterol are AMPK‐dependent. In conclusion, this study highlights the therapeutic potential of β‐sitosterol in UC through modulation of the AMPK/MLCK signaling pathway. These findings not only deepen our understanding of β‐sitosterol's anti‐inflammatory properties but also suggest its potential in developing novel AMPK‐targeted therapies for inflammatory bowel disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, China.
- Department of Pharmacy, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, China.
Förderung
- This study was supported by the Science and Technology Program of Wenzhou (Y2023393).
Zitieren
APA
Zhang, Y., Jin, X., Xia, H., Wu, X., Chen, W., Zhuang, M., & Tang, S. (2025). β‐Sitosterol Ameliorates Ulcerative Colitis Through Modulation of the AMPK/MLCK Anti‐Inflammatory Pathway. Journal of Biochemical and Molecular Toxicology, 39(6). https://doi.org/10.1002/jbt.70287
Vancouver
Zhang Y, Jin X, Xia H, Wu X, Chen W, Zhuang M, et al. β‐Sitosterol Ameliorates Ulcerative Colitis Through Modulation of the AMPK/MLCK Anti‐Inflammatory Pathway. Journal of Biochemical and Molecular Toxicology. 2025;39(6). doi:10.1002/jbt.70287
BibTeX
@article{Zhang2025,
author = {Zhang, Yuansen and Jin, Xiaosheng and Xia, Huanhuan and Wu, Xiaoqiu and Chen, Wenjun and Zhuang, Mengxiao and Tang, Sensen},
title = {β‐Sitosterol Ameliorates Ulcerative Colitis Through Modulation of the AMPK/MLCK Anti‐Inflammatory Pathway},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
volume = {39},
number = {6},
doi = {10.1002/jbt.70287}
}
EUVIMED